Platinum OpinionCytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered
Section snippets
Conflicts of interest
Alain Ravaud and Arnaud Méjean are co-Chief Investigators of CARMENA. Michael Aitchison was the UK lead investigator for CARMENA. Axel Bex is the co-Chief Investigator for SURTIME. The remaining other authors have nothing to disclose.
Acknowledgments: CARMENA is sponsored by Assistance Publique-Hôpitaux de Paris (APHP). CARMENA-UK was funded by Cancer Research UK and administered by the CRUK Clinical Trials Unit, The Beatson West of Scotland Cancer Centre, Glasgow. SURTIME was sponsored by the
References (8)
- et al.
European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
Lancet
(2001) - et al.
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium
Eur Urol
(2014) Surgical research or comic opera: questions, but few answers
Lancet
(1996)- et al.
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
N Engl J Med
(2001)
Cited by (21)
The role and timing of cytoreductive nephrectomy in the immunotherapy era
2020, European Urology FocusResponse of Primary Renal Cell Carcinoma to Systemic Therapy
2019, European UrologyCitation Excerpt :Most patients were Memorial Sloan Kettering Cancer Center (MSKCC) intermediate risk (87%). The study closed early due to poor accrual, but showed no difference in the progression-free rate at 28 wk (42% vs 43%, two-sided p > 0.9) and fewer surgical complications in the deferred CRN arm (28% vs 44%) [10]. The phase III non-inferiority trial CARMENA randomized patients to upfront CRN followed by sunitinib or sunitinib alone [12].
Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?
2019, European Urology OncologyCitation Excerpt :Eight years were necessary to accrue 450 of a planned 576 patients over 79 sites. This corresponds to fewer than one patient per year at each institution and suggest that many potentially eligible patients were never enrolled due to either clinicians’ lack of clinical equipoise or patient unwillingness to be randomised [14]. As expected, a comparative analysis [15] of the baseline characteristics of patients captured in the National Cancer Database relative to CARMENA participants revealed that the latter had more metastatic sites involved and more severe burden of metastasis in lymph nodes.
Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era
2018, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :Nevertheless, the presented risk scores are optimized to the targeted therapy era and may serve as valuable risk stratification tools in clinical practice. Our findings warrant prospective evaluation; however, accrual difficulties to prospective trials including CN have been well documented, and in the meantime we must rely on data such as these to facilitate decision-making [29]. We developed two risk scores using readily available patient features to enhance prediction of CSS after CN in contemporary clinical practice.
Morbidity of Metastasectomy for Renal Cell Carcinoma: Emerging Evidence and Unmet Needs
2017, European Urology